Does Zilucoplan work?
Yes, in a controlled trial of 174 patients.
Approval rests on RAISE, a 174-patient randomized placebo-controlled phase 3 trial that met its primary endpoint on the patient-reported MG-ADL scale at 12 weeks, plus a phase 2 trial. The approved use matches the trial population, so A; durability beyond 12 weeks comes from open-label extension data and a 48-patient French early-access cohort followed for six months without a control group. 123
Lancet Neurology published RAISE in 2023. It randomized 174 adults at 75 sites in Europe, Japan and North America. All had generalized myasthenia gravis and antibodies to that receptor. They got zilucoplan or placebo for 12 weeks. The Myasthenia Gravis Activities of Daily Living score is an 8-item scale. Patients report it. It improved by 4.39 points on zilucoplan versus 2.30 on placebo, a difference of 2.09 points. The Quantitative Myasthenia Gravis scale is scored by clinicians. It improved by 6.19 versus 3.25 points. Gains showed by the first week. 1
People from RAISE could join open-label extension studies. The label reports safety data from 213 patients in those studies. Seven of them (3.3 percent) had pancreatic events. 2
Evidence checklist
- Randomised controlled trial RAISE, placebo-controlled phase 3
- Human study over 100 people RAISE enrolled 174 patients
- More than one research group Trials from the developer, UCB; a 48-patient French hospital cohort (2026) reported similar gains but had no control group
- Clinical outcomes, not surrogate markers Patient-reported MG-ADL scale
- Human safety data beyond case reports Boxed meningococcal warning from trials
More on Zilucoplan
Citations
- Howard 2023, Lancet Neurol: Safety and efficacy of zilucoplan in generalized myasthenia gravis (RAISE), phase 3 trial doi.org
- FDA 2024: Zilbrysq (zilucoplan) prescribing information accessdata.fda.gov
- Tammam 2026, J Neuromuscul Dis: Real-world effectiveness and safety of zilucoplan in anti-AChR myasthenia gravis, French early-access cohort pubmed.ncbi.nlm.nih.gov
Reference information only, not medical advice. Drawn from the Zilucoplan article, fact-checked against the cited sources. No dosing anywhere on this site.